Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

RADIANCE Modest Renal Denervation Effect Remains at 6 Months

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

October 31, 2023

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

September 18, 2022

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

News Conference News TCT 2022

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

September 18, 2022

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

News Opinion Editor's Corner TCT 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

November 01, 2021

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

September 26, 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

September 25, 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

September 25, 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presentation TCT 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presenter: John A. Bittl, Bernard J. Gersh, Michael A. Weber

September 24, 2018

Patient Perspectives on Sham-Controlled Trials

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

News Conference News TCT 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

September 23, 2018

FDA Perspectives on Sham-Controlled Trials

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presentation TCT 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Rasha Al-Lamee

September 23, 2018

Untreated Accessory Arteries Dampen Renal Denervation Response: RADIANCE-HTN SOLO

News Conference News TCT 2018

Untreated Accessory Arteries Dampen Renal Denervation Response: RADIANCE-HTN SOLO

September 21, 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

September 17, 2018

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Presentation TCT 2016

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

News Features TCT 2014

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

October 31, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.